Clinical Trial Update: Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of XIAP antisense oligonucleotide given with chemotherapy for refractory/relapsed acute myelomonocytic leukemia has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelomonocytic Leukemia

Drugs mentioned

• XIAP antisense (XIAP antisense oligonucleotide)

Snippet

Sponsor: Aegera Therapeutics | Conditions: Leukemia, Myelomonocytic, Acute | Phase 1, Phase 2 | Status: COMPLETED